tirzepatide vs semaglutide clinical trials of subcutaneous tirzepatide, retatrutide, and Tirzepatide as Compared with Semaglutide

Importantly, when GLP-1 therapy was combined with lifestyle changes, outcomes were stronger than either strategy alone

Referral is recommended when the diagnosis is unclear, lesions are atypical, or systemic involvement is suspected

Wegovy: Conditions treated Qsymia and Wegovy are both approved for chronic weight management in people with obesity who have a body mass index (BMI) of 30 or higher

Common injection sites include the abdomen, thigh, or upper arm, with rotation between sites recommended to prevent injection site reactions

Key Takeaways Starting dose: 2mg once weekly for the first 4 weeks to assess tolerance Titration schedule: Increase every 4 weeks: 2mg 4mg 8mg 12mg (max) Half-life: Approximately 6 days, reaching steady state in 4-5 weeks Injection frequency: Once weekly on the same day each week Microdosing option: Some users split doses for improved tolerability Investigational Drug: Retatrutide is NOT FDA-approved and is currently only available through clinical trials